 The primary objective of the study is to evaluate the safety of 3 different dosages 20μg - 50μg and 100μg of a placental malaria vaccine candidate PRIMVAC vaccine adjuvanted either with Alhydrogel or GLA-SE, and administered at D0, D28 and D56 in healthy European and Burkinabe adults. 